Lens Epithelial Cell Proliferation In Patients Suffering From Diabetes And Treated With Metformin In Vitro: A Pilot Study
Published 2023 - 41st Congress of the ESCRS
Reference: FP21.07 | Type: Free paper | DOI: 10.82333/ez73-ns44
Authors: Christoph Spartalis* 1 , Martin Kronschläger 1 , Manuel Ruiss 2 , Thomas Dechat 3 , Thomas Köcher 4 , Christoph Leisser 1 , Oliver Findl 1
1Department of Ophthalmology ,Hanusch Hospital Vienna,Vienna,Austria, 2Vienna Institute for Research in Ocular Surgery,Vienna,Austria, 3Ludwig Boltzmann Institute of Osteology,Vienna,Austria, 4Vienna BioCenter Core Facilities,Vienna,Austria
Purpose
PCO develops in about 20-30% of patients after cataract surgery. The cause are residual lens epithelial cells (LECs). Metformin is a often used drug for treatment in type II diabetics. Experimental studies showed an inhibition of PCO formation by metformin. Lower Nd:YAG laser capsulotomy rates have also been reported.
To our knowledge it remains unclear which impact the intake of metformin in humans suffering from type II diabetics has on LEC proliferation in vitro. Moreover, it is unknown which concentration of metformin can be expected in the human lens capsule as well as in the vitreous, when systemically applied.
Our purpose is to determine the concentration of metformin and proliferation rates of LECs under its influence.
Setting
Vienna Institute for Research in Ocular Surgery (VIROS)
Methods
The concentration of metformin in the lens capsule, vitreous and serum will be evaluated in 40 patients with type II diabetes. Samples will be collected during cataract or vitreous surgery. Concentrations in the lens capsules, vitreous and blood serum are determined by high performance liquid chromatography.
The effect of metformin on the proliferation of LECs will be investigated using 80 lens capsules in vitro.
The proliferation rates of LECs will be determined using CYTOSmart Omni FL microscope, which allows "live cell imaging".
The current study is performed in accordance with the Declaration of Helsinki and approved by the local ethics committee of Vienna, Austria (EK 22-192-0922).
Results
The concentration of Metformin has already been determind in 10 lens capsules, 2 vitreous and 12 blood serum samples.
The data show concentrations 0,06-1,14 pg/µl in the lens capsules, 7,97 pg/µl in the vitreous and 6,4-320,2 pg/µl in the serum samples.
Data will be collected continuously until the presentation. The then current results and the further outlook of the still ongoing study will be presented.
Conclusions
Metformin is detectable in the lens capsule, vitreous humor and blood serum by high performance liquid chromatography. Current data show differences in capsule, vitreous and serum concentrations, with serum concentrations being highest and capsule concentrations being lowest.
Correlation analyses and further data will be available by the time of presentation. The same applies to the proliferation rates.